Christopher Heery, MD, medical oncologist, National Cancer Institute, discusses the potential underlying benefits of combination therapy in the treatment of patients with gastrointestinal (GI) cancers.
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More